Omeprazole (API)
Proton pump inhibitor API aligned to global pharmacopoeial monographs. Suitable for delayed release pellets, tablets, and suspensions targeting acid suppression therapies.
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
Our APIs are engineered with precision and purity, ensuring consistent therapeutic performance and global regulatory compliance.
Enteric Coated Pellets • Sustained Release Pellets • Micro Pellets • DC Granules • APIs
Proton pump inhibitor API aligned to global pharmacopoeial monographs. Suitable for delayed release pellets, tablets, and suspensions targeting acid suppression therapies.
High-purity pantoprazole sodium sesquihydrate meeting major pharmacopoeial specifications. Controlled particle size supports pelletisation, tablet, and injectable development pipelines.
Benzoimidazole-class PPI API manufactured under WHO-GMP. Offers low related substances and is optimised for rapid conversion to enteric pellets or tablets.
Triazole antifungal API with validated controls on isomer and solvent content. Supports capsule, tablet, and IV dosage manufacturing for systemic mycoses.
Broad-spectrum anthelmintic API processed to deliver excellent polymorphic stability and tight assay results for chewable or solid oral dose forms.
As India's leading pellets manufacturer, we offer pharmaceutical pellets R&D pilot scale development, pellet coating services India, third party manufacturing tablets India, and contract manufacturing pharma India. Our CDMO India team provides DMF access, stability data, pharmaceutical technology transfer services, and custom formulations for omeprazole, lansoprazole, domperidone SR, and tamsulosin SR pellets.